Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists

被引：63
作者：
Beach, TG
Walker, DG
Potter, PE
Sue, LI
Fisher, A
机构：
[1] Sun Hlth Res Inst, Sun City, AZ 85372 USA
[2] Midwestern Univ, Glendale, AZ USA
[3] Israel Inst Biol Res, IL-74100 Ness Ziona, Israel
来源：
BRAIN RESEARCH | 2001年 / 905卷 / 1-2期
基金：
美国国家卫生研究院;
关键词：
Alzheimer's disease; cholinergic; therapy; amyloid beta; muscarinic agonists; cerebrospinal fluid;
D O I：
10.1016/S0006-8993(01)02484-2
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Overproduction of the peptide amyloid beta (A beta) is a critical event in Alzheimer's disease (AD). Systemic administration of 3 Mi-selective muscarinic agonists, AF102B, AF150S and AF267B, decreased cerebrospinal fluid (CSF) A beta concentrations; levels of CSF secreted beta -APP were not significantly altered. Rabbits treated for 5 days with s.c. injections of each drug (2 mg/kg/day) had levels of CSF A beta which were between 55 and 71% of control for A beta 1-40 and between 59 and 84% of control for A beta 1-42. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：220 / 223
页数：4
相关论文
共 23 条
[1]   Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].
Andreasen, N ;
Hesse, C ;
Davidsson, P ;
Minthon, L ;
Wallin, A ;
Winblad, B ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680
[2]   Increased beta-amyloid precursor protein mRNA in the rat cerebral cortex and hippocampus after chronic systemic atropine treatment [J].
Beach, TG ;
Walker, DG ;
Cynader, MS ;
Hughes, LH .
NEUROSCIENCE LETTERS, 1996, 210 (01) :13-16
[3]  
ECKOLS K, 1995, LIFE SCI, V12, P83
[4]  
FARBER SA, 1995, J NEUROSCI, V15, P7442
[5]  
Fisher A, 2000, DRUG DEVELOP RES, V50, P291, DOI 10.1002/1098-2299(200007/08)50:3/4<291::AID-DDR12>3.0.CO
[6]  
2-6
[7]  
Fisher A, 1997, Expert Opin Investig Drugs, V6, P1395, DOI 10.1517/13543784.6.10.1395
[8]   Muscarinic receptor agonists in Alzheimer's disease - More than just symptomatic treatment? [J].
Fisher, A .
CNS DRUGS, 1999, 12 (03) :197-214
[9]  
Haring R, 1998, J NEUROCHEM, V71, P2094
[10]   Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions [J].
Haroutunian, V ;
Greig, N ;
Pei, XF ;
Utsuki, T ;
Gluck, R ;
Acevedo, LD ;
Davis, KL ;
Wallace, WC .
MOLECULAR BRAIN RESEARCH, 1997, 46 (1-2) :161-168
123